Sign In Solutions’ Founder Hands CEO Reins to Scott Meyer, Moves Into Advisory Role
Transition marks next phase of Sign In Solutions’ evolution, uniting security, governance, and seamless experiences under new leadership ST. PETERSBURG, Fla.,... Read more.
10Bridge Unveils AI Agents for Healthcare Data Interoperability Workflows
New AI Agent Automation eliminates manual reporting, automates complex interoperability tasks, and enables system integration when APIs or technical expertise are... Read more.
2025: Landmark AI Progress for Quickplay, Delivering Business Impact for Broadcasters in a Creator-Driven World
Quickplay’s AI achievements surpass industry hype, transforming emerging trends intoundeniable reality including 100%+ watch time increases, 130%+ ad fill... Read more.
Echo Global Logistics Announces EchoXBorder: Expanded Cross-Border Solutions for U.S. and Mexico
EchoXBorder marks the latest addition to Echo’s growing cross-border operations CHICAGO, Jan. 6, 2026 /PRNewswire/ — Echo Global Logistics, Inc. (“Echo”),... Read more.
Wilmington Trust 2026 Capital Markets Forecast: Investing in a Period of Economic Experimentation
Outlook highlights risks and opportunities investors face amid period of high tariffs, shrinking labor force and the continued U.S. debt trajectory WILMINGTON, Del.,... Read more.
Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum
BOSTON, Jan. 6, 2026 /PRNewswire/ — Bambusa Therapeutics, Inc., a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for... Read more.
Westlake Securities Advises NaturPak on Sale to PPC
AUSTIN, Texas, Jan. 6, 2026 /PRNewswire/ — Westlake Securities (“Westlake”), a leading Texas-based middle-market investment bank, today announced... Read more.
Lung Cancer Research Foundation Announces Additional 2025 Scientific Research Grant Awards
Foundation funds five new research projects, bringing 2025 total to $5.2 million NEW YORK, Jan. 6, 2026 /PRNewswire/ — The Lung Cancer Research Foundation®... Read more.
Dark Blue Therapeutics acquired by Amgen for up to $840 million
Lead candidate in the MLLT1/3 programme, DBT 3757, is a differentiated investigational molecule designed to treat Acute Myeloid Leukemia Acquisition brings a new... Read more.
Gilgamesh Pharma Announces Positive Topline Phase 2a Results for Blixeprodil (GM-1020) in Major Depressive Disorder
Blixeprodil, a novel, oral NMDA receptor antagonist, demonstrated rapid, robust, and durable antidepressant effects in Major Depressive Disorder Rapid and robust... Read more.